Compare Enveric Biosciences Inc (ENVB) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hershey Co — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Hershey Co trades at $162.74 (market cap $32.66B). The key difference: Hershey Co is far larger — about 4802.9× Enveric Biosciences Inc's market cap, and Hershey Co pays a 3.57% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Hershey Co for 135 Days on average.
| ENVB | HSY | |
|---|---|---|
Market Cap | $6.80M | $32.66B |
Volume | 64,867 | 1,578,237 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $236.28 |
52-Week Low | $1.27 | $157.61 |
Typical Hold Time | 14 Days | 135 Days |
Enterprise Value | -$1.49M | $37.79B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
Hershey (HSY) trades at $162.74, up 1.5% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats (3 of last 4 quarters) with Q3 2026 results pending. Revenue grew to $11.69B in 2025, though net margin compressed to 7.55% from 19.82% in 2024. Analyst consensus targets $204.62 (25.7% upside) with 65.7% hold ratings. Recent news highlights dividend resumption and international leadership changes.
HSY presents a mixed outlook: valuation appears reasonable (P/E 22.2) with strong brand positioning, but faces margin pressure from commodity costs. The technical bearish trend near key support at $161 suggests near-term caution. Long-term investors may find value given dividend growth resumption and consistent market share, though cocoa price volatility remains a key risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
